Jun 18, 2026
HS Codes for Pharmaceuticals and Medical Devices: Classification, Duty Rates, and FDA-CBP Overlap
Pharmaceutical and medical device imports cross five HTSUS chapters (28, 29, 30, 38, and 90), one Pharmaceutical Appendix, multiple FTA programs, the Section 301 China overlay, and the Section 232 patented-pharma proclamation issued April 2, 2026. Each entry is also an FDA admissibility decision routed through ACE/ITDS, PREDICT risk scoring, and mandatory Affirmation of Compliance codes. Getting classification right is the entry point to every other compliance question, including which duties apply, which exclusions are available, and whether the entry releases or detains.
Which HTSUS Chapters Cover Pharmaceuticals and Medical Devices?
Five chapters carry the bulk of classifications:
Chapter 28: Inorganic chemicals, including radiopharmaceutical precursors (heading 2844) and inorganic APIs
Chapter 29: Separate chemically defined organic compounds (most APIs) concentrated under 2936 (vitamins), 2937 (hormones), 2939 (alkaloids), and 2941 (antibiotics), with modern APIs under 2933, 2934, and 2935
Chapter 30: Pharmaceutical products: 3002 (biologics), 3003 (bulk medicaments), 3004 (finished dosage-form drugs), 3006 (enumerated special pharmaceutical goods)
Chapter 38: Non-patient diagnostic laboratory reagents under heading 3822
Chapter 90: Medical devices: 9018 (instruments), 9019 and 9020 (breathing apparatus), 9021 (orthopedic appliances, hearing aids, pacemakers, and implants)
Chapter 30 Note 1 exclusions override any pharmaceutical claim regardless of labeling:
Food supplements and nutraceuticals belong in heading 2106
Cosmetics with therapeutic claims fall to 3303 to 3307
Nicotine cessation patches and gums move to 2404 under the 2025 Note 1(b) revision
Non-patient laboratory reagents belong in 3822 (Chapter 38)
The critical classification boundary inside Chapter 30 is between 3003 and 3004. Chapter 30 Note 3 makes the test "mixed versus unmixed" rather than "formulated versus unformulated." An API in Chapters 28 or 29 dissolved in water is still "unmixed," so a single API in a vial of water for injection is not automatically a 3003 product.
How to Classify APIs, Finished Drugs, and Medical Devices
Classifying an Active Pharmaceutical Ingredient
Confirm separate-chemically-defined status under Chapter 29 Note 1. Multi-component mixtures of different APIs are not Chapter 29 goods.
Map chemical structure to the Chapter 29 heading by carbon-skeleton class and functional group: ibuprofen (propionic acid derivative) to 2916.39, atorvastatin (nitrogen heterocyclic) to 2933.99, amoxicillin to 2941.10.
Check whether the heading carries the K symbol in the Special Rates column. If yes, the INN may qualify for duty-free treatment under General Note 13 (the Pharmaceutical Appendix) if it appears in Table 1 of the current USITC appendix.
Claim "Free (K)" at entry. Missed K preferences are recoverable by protest within 180 days of liquidation.
Classifying a Finished Drug
Verify the product is not excluded by Chapter 30 Note 1.
Determine the Chapter 30 heading:
3002: Blood, biologics, and immunological products
3003: Bulk medicaments without measured doses or retail packaging
3004: Medicaments in measured doses or retail packaging (primary finished-drug heading)
3006: Sterile sutures, contrast agents, ostomy appliances, and dental cements (Note 4 mandatory allocation)
Inside 3004, the 8-digit subheading is rate-determinative: 3004.10 penicillins, 3004.20 other antibiotics, 3004.31 insulin, 3004.32 corticosteroids, 3004.39 other hormones, 3004.41 alkaloids, 3004.50 vitamin-containing, 3004.60 antimalarials, 3004.90 residual basket. Ten-digit suffixes are statistical only.
Classifying a Medical Device
Check for drug-device combination status first. If the product is a combination, run GRI 3(b) essential character analysis before assuming Chapter 90. A drug-eluting stent lands in 9021 (device structure is essential character). A prefilled syringe lands in the drug heading (drug is the essential commercial identity).
For purely mechanical devices, identify the correct heading: 9018 (medical, surgical, dental, and veterinary instruments), 9019 and 9020 (breathing apparatus), or 9021 (orthopedic appliances, hearing aids, pacemakers, implants).
Always check Nairobi Protocol eligibility under 9817.00.92, 9817.00.94, and 9817.00.96. CBP has approved cochlear implants, insulin pumps, pacemakers, prosthetic limbs, CPAP masks, and ostomy appliances under these subheadings. Section 9817 duty-free treatment overrides all other tariff provisions, including Section 301 and Section 232, making it one of the few mechanisms that eliminates multiple tariff layers simultaneously.
Duty Rates, Tariff Overlays, and Regulatory Changes Before September 2026
MFN baseline and Pharmaceutical Appendix
Chapters 30 and 90 are generally duty-free at MFN. Chapter 29 APIs are mostly duty-free, with select subheadings under 2933 to 2935 carrying 3.7% or 6.5%.
The Pharmaceutical Appendix (General Note 13) covers APIs with non-zero MFN rates where the HTS subheading carries the K symbol and the INN appears in Table 1. The 2026 appendix is downloadable from USITC. It does not extend to Chapter 30 or 90 goods (already MFN-free).
FTA preferences
USMCA: duty-free for qualifying Chapter 29, 30, and 90 goods through the Chemical Reaction Rule and tariff-shift tests
KORUS: full tariff elimination within three years
November 2025 U.S.-Korea framework is reported to cap Section 232 pharmaceutical tariff for Korean-origin products at 15% (verify against the bilateral agreement text)
Section 301 China overlay
Chapter 30 finished pharmaceuticals from China are generally at 0% Section 301. The September 27, 2024 final modifications targeted specific device categories:
Syringes and needles (9018.31, 9018.32): 100%
Respirators and surgical face masks: 25% in 2024, rising to 50% in 2026
Rubber medical and surgical gloves: 100% effective January 1, 2026
Enteral syringes: 100% effective January 1, 2026
Verify all current rates against USTR's active Section 301 schedule before filing, as rates and exclusions change frequently.
Section 232 pharmaceutical tariff (verify all details against the Federal Register proclamation)
The April 2, 2026 Presidential Proclamation is reported to impose a 100% baseline ad valorem tariff on patented pharmaceuticals listed in the FDA Orange Book or Purple Book, plus their APIs and key starting materials. Reported key terms:
Effective July 31, 2026 for Annex III companies and September 29, 2026 for all others
Generics and biosimilars exempt initially, with Commerce reviewing within one year
UK pharmaceutical exports reportedly tariff-free for at least three years under a bilateral agreement
IEEPA status: IEEPA tariffs affecting pharma are reported as invalidated following a February 2026 Supreme Court ruling in Learning Resources, Inc. v. Trump (verify against primary legal sources and CBP bulletins before adjusting entry positions). Section 301, as congressional delegation authority, was unaffected.
FDA-CBP Coordination, AofC Codes, and Common Classification Mistakes
Entry workflow and PREDICT scoring
Every FDA-regulated pharmaceutical and device entry flows through ACE/ITDS. FDA's PREDICT scores each line in real time across three input categories:
Facility-level: registration status, inspection history, import alert status
Product-level: FDA product code, country of origin, prior lab results
Shipment-level: port, importer history, declared-versus-expected discrepancies
PREDICT produces one of four dispositions: May Proceed (release), FDA Review (documentary exam), Examination (physical inspection or sampling), or Detention (formal Notice of Detention and Hearing under 21 CFR Part 1).
Mandatory Affirmation of Compliance codes
The FDA ACE Supplemental Guide (March 2025) governs which codes apply by product category. Core codes:
DA: Drug Application Number (NDA, ANDA, or BLA, with qualifier)
DLS: National Drug Code (with qualifier), verified automatically against the FDA NDC Directory
BLN: Biologics License Number (replaces DA for biologics)
DEV: Device Foreign Manufacturer Registration
DFE: Device Foreign Exporter Registration
DDM: Device Domestic Manufacturer
DI: Device Identifier under UDI
HCT: Human Cells and Tissue
Entries missing mandatory codes or carrying incorrect NDCs trigger ACE rejection, examination, or detention. Note: the Prior Notice requirement under 21 CFR Part 1, Subpart I applies to food, not to drugs or medical devices.
Six classification mistakes that cost importers the most
Filing a finished drug under a Chapter 29 API heading: atorvastatin tablets classify under 3004.90, not 2933.99. GRI 3(a) makes 3004 more specific for the formulated product, and FDA requires different mandatory AofC codes.
Missing the K preference: when a Chapter 29 heading carries the K symbol and the INN appears in Table 1, the duty-free rate under General Note 13 must be claimed explicitly in ACE.
Missing or incorrect AofC codes: trigger immediate ACE rejection and examination, with storage costs and disrupted release.
Classifying lab-only diagnostic reagents in 3002: bulk reagents for clinical chemistry laboratories belong in 3822. The patient-versus-laboratory distinction controls.
Misclassifying drug-device combinations without GRI 3(b): obtain a CBP Binding Ruling via CROSS before importing novel configurations.
Overlooking Nairobi Protocol relief (9817.00.96): cochlear implants, insulin pumps, pacemakers, and prosthetic limbs can eliminate Section 301 and Section 232 layers simultaneously.
Manage Pharma Trade Compliance with Gaia Dynamics
Pharmaceutical teams managing branded, generic, biosimilar, and device portfolios across multiple HTSUS chapters, FTA programs, and rapidly shifting tariff overlays face a workflow problem that manual classification processes cannot solve at scale. The Section 232 proclamation's Annex lists, Section 301 exclusion expirations, and PREDICT risk-scoring changes all require entry-level position updates on timelines that compress from weeks to days.
Gaia Dynamics provides workflow tools that combine HTS classification, real-time tariff calculation, and continuous regulatory monitoring to compress the time between a Federal Register notice and an updated entry-level position. For retroactive audit on entries filed under the IEEPA layer between April 2025 and February 2026, refund eligibility for qualifying entries runs through the CAPE module inside ACE.
Frequently Asked Questions
Does the Section 232 100% pharmaceutical tariff apply to generics?
No. Generics and biosimilars are exempt from the April 2, 2026 proclamation as initially issued (verify against Federal Register text). Commerce is directed to re-evaluate the exemption within one year. Branded patented pharmaceuticals in the Orange Book or Purple Book face the 100% baseline rate.
Can a Chinese-origin API still claim the Pharmaceutical Appendix K preference?
Chinese-origin APIs generally are not eligible for Pharmaceutical Appendix K. General Note 13 requires column 1 eligibility and Appendix coverage, so verify origin, classification, and the current appendix before assuming duty-free treatment; then separately check any Section 301 duty or exclusion.
How does a 9817.00.96 Nairobi Protocol claim interact with Section 301 and Section 232?
Section 9817 overrides all other tariff provisions, including Section 301 and Section 232. The two-part test requires the article to benefit physically or mentally handicapped persons permanently. File the claim at entry and review CBP CROSS for ruling precedents matching the specific device.
What FDA AofC codes are required for a finished drug import?
The standard set includes DA (Drug Application Number, with qualifier), DLS (NDC, with qualifier), and the foreign manufacturer's establishment registration. Biologics substitute BLN for DA. Devices use DEV, DFE, DDM, and DI as applicable. Missing or incorrect codes trigger ACE rejection. The FDA ACE Supplemental Guide (March 2025) governs mandatory codes by product category.
